Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunction3',5'-cyclic-AMP phosphodiesterase activity

PDE6B PDE6C

1.73e-052262GO:0004115
GeneOntologyMolecularFunction3',5'-cyclic-GMP phosphodiesterase activity

PDE6B PDE6C

2.07e-052462GO:0047555
GeneOntologyMolecularFunction3',5'-cyclic-nucleotide phosphodiesterase activity

PDE6B PDE6C

2.25e-052562GO:0004114
GeneOntologyMolecularFunctioncyclic-nucleotide phosphodiesterase activity

PDE6B PDE6C

2.63e-052762GO:0004112
GeneOntologyMolecularFunctionphosphoric diester hydrolase activity

PDE6B PDE6C

3.46e-049762GO:0008081
GeneOntologyMolecularFunctionphosphoric ester hydrolase activity

PDE6B PDE6C

5.31e-0338662GO:0042578
GeneOntologyBiologicalProcessphototransduction, visible light

PDE6B PDE6C

1.34e-052062GO:0007603
GeneOntologyBiologicalProcessphototransduction

PDE6B PDE6C

9.65e-055362GO:0007602
GeneOntologyBiologicalProcessdetection of visible light

PDE6B PDE6C

1.12e-045762GO:0009584
GeneOntologyBiologicalProcesscAMP-mediated signaling

PDE6B PDE6C

1.99e-047662GO:0019933
GeneOntologyBiologicalProcessdetection of light stimulus

PDE6B PDE6C

2.04e-047762GO:0009583
GeneOntologyBiologicalProcessdetection of external stimulus

PDE6B PDE6C

1.03e-0317362GO:0009581
GeneOntologyBiologicalProcessdetection of abiotic stimulus

PDE6B PDE6C

1.05e-0317562GO:0009582
GeneOntologyBiologicalProcessretina development in camera-type eye

PDE6B PDE6C

1.52e-0321162GO:0060041
GeneOntologyBiologicalProcessvisual perception

PDE6B PDE6C

1.80e-0323062GO:0007601
GeneOntologyBiologicalProcesssensory perception of light stimulus

PDE6B PDE6C

1.85e-0323362GO:0050953
GeneOntologyBiologicalProcesspositive regulation of GTPase activity

FERMT2 TBC1D9

2.03e-0324462GO:0043547
GeneOntologyBiologicalProcessregulation of GTPase activity

FERMT2 TBC1D9

3.78e-0333562GO:0043087
HumanPhenoAbnormal full-field electroretinogram

PDE6B PDE6C

2.56e-048222HP:0030466
HumanPhenoAttenuation of retinal blood vessels

PDE6B PDE6C

7.61e-0414122HP:0007843
HumanPhenoColor vision defect

PDE6B PDE6C

9.68e-0415922HP:0000551
HumanPhenoCongenital stationary cone dysfunction

PDE6B PDE6C

1.02e-0316322HP:0030637
HumanPhenoAbnormal electroretinogram

PDE6B PDE6C

1.96e-0322622HP:0000512
HumanPhenoAbnormal visual electrophysiology

PDE6B PDE6C

2.84e-0327222HP:0030453
HumanPhenoPhotophobia

PDE6B PDE6C

3.03e-0328122HP:0000613
HumanPhenoHypermetropia

PDE6B PDE6C

3.19e-0328822HP:0000540
HumanPhenoAbnormal retinal vascular morphology

PDE6B PDE6C

3.43e-0329922HP:0008046
HumanPhenoRetinal degeneration

PDE6B PDE6C

3.50e-0330222HP:0000546
HumanPhenoVisual field defect

PDE6B PDE6C

3.53e-0330322HP:0001123
HumanPhenoSensory hypersensitivity

PDE6B PDE6C

3.91e-0331922HP:5200058
HumanPhenoSensory behavioral abnormality

PDE6B PDE6C

4.36e-0333722HP:5200046
HumanPhenoAbnormality of the vasculature of the eye

PDE6B PDE6C

6.91e-0342422HP:0008047
HumanPhenoAbnormal chorioretinal morphology

PDE6B PDE6C

7.01e-0342722HP:0000532
HumanPhenoRetinal dystrophy

PDE6B PDE6C

7.48e-0344122HP:0000556
HumanPhenoAbnormal choroid morphology

PDE6B PDE6C

7.51e-0344222HP:0000610
HumanPhenoMyopia

PDE6B PDE6C

7.68e-0344722HP:0000545
HumanPhenoAbnormality of retinal pigmentation

PDE6B PDE6C

8.14e-0346022HP:0007703
HumanPhenoAbnormality of the retinal pigment epithelium

PDE6B PDE6C

8.14e-0346022HP:0008051
HumanPhenoAplasia/Hypoplasia of the retina

PDE6B PDE6C

8.79e-0347822HP:0008061
HumanPhenoReduced visual acuity

PDE6B PDE6C

1.33e-0258922HP:0007663
MousePhenodecreased retina photoreceptor cell number

PDE6B PDE6C

1.65e-047442MP:0001327
MousePhenoabnormal cone electrophysiology

PDE6B PDE6C

2.89e-049842MP:0004022
MousePhenoretina photoreceptor degeneration

PDE6B PDE6C

3.71e-0411142MP:0008450
MousePhenodecreased sensory neuron number

PDE6B PDE6C

9.83e-0418142MP:0000966
MousePhenoabnormal retina photoreceptor morphology

PDE6B PDE6C

1.27e-0320642MP:0001004
MousePhenoabnormal retina photoreceptor layer morphology

PDE6B PDE6C

1.38e-0321542MP:0003728
MousePhenoabnormal eye electrophysiology

PDE6B PDE6C

1.56e-0322842MP:0005551
MousePhenodecreased neuron number

PDE6B PDE6C

4.18e-0337642MP:0008948
MousePhenoneuron degeneration

PDE6B PDE6C

4.51e-0339142MP:0003224
MousePhenoabnormal retina neuronal layer morphology

PDE6B PDE6C

5.71e-0344142MP:0006069
MousePhenoabnormal neuron number

PDE6B PDE6C

6.10e-0345642MP:0008946
MousePhenoneurodegeneration

PDE6B PDE6C

6.42e-0346842MP:0002229
MousePhenoabnormal sensory neuron morphology

PDE6B PDE6C

6.55e-0347342MP:0000965
MousePhenoabnormal retina layer morphology

PDE6B PDE6C

7.42e-0350442MP:0003727
MousePhenoabnormal eye physiology

PDE6B PDE6C

1.06e-0260642MP:0005253
MousePhenoabnormal somatic sensory system morphology

PDE6B PDE6C

1.41e-0270242MP:0000959
DomainGAF

PDE6B PDE6C

1.80e-06762PF01590
DomainGAF

PDE6B PDE6C

2.41e-06862SM00065
DomainGAF

PDE6B PDE6C

2.41e-06862IPR003018
Domain-

PDE6B PDE6C

3.09e-069623.30.450.40
DomainGAF_dom-like

PDE6B PDE6C

3.09e-06962IPR029016
DomainPDEase

PDE6B PDE6C

1.47e-051962IPR023088
DomainPDEase_I

PDE6B PDE6C

1.80e-052162PF00233
DomainPDEASE_I

PDE6B PDE6C

1.80e-052162PS00126
DomainPDEase_CS

PDE6B PDE6C

1.80e-052162IPR023174
Domain-

PDE6B PDE6C

1.98e-0522621.10.1300.10
DomainPDEase_catalytic_dom

PDE6B PDE6C

2.17e-052362IPR002073
DomainHDc

PDE6B PDE6C

2.37e-052462SM00471
DomainHD/PDEase_dom

PDE6B PDE6C

2.37e-052462IPR003607
PathwayWP_PHOSPHODIESTERASES_IN_NEURONAL_FUNCTION

PDE6B PDE6C

8.92e-055542M39763
PathwayKEGG_PURINE_METABOLISM

PDE6B PDE6C

7.47e-0415942M14314
PathwayWP_PURINE_METABOLISM

PDE6B PDE6C

8.64e-0417142MM15909
Pubmed

Systematic spatiotemporal mapping reveals divergent cell death pathways in three mouse models of hereditary retinal degeneration.

PDE6B PDE6C

2.48e-0826231710697
Pubmed

Cone Phosphodiesterase-6γ' Subunit Augments Cone PDE6 Holoenzyme Assembly and Stability in a Mouse Model Lacking Both Rod and Cone PDE6 Catalytic Subunits.

PDE6B PDE6C

2.48e-0826230038560
Pubmed

Calcium dynamics change in degenerating cone photoreceptors.

PDE6B PDE6C

2.48e-0826227402880
Pubmed

Exchange of Cone for Rod Phosphodiesterase 6 Catalytic Subunits in Rod Photoreceptors Mimics in Part Features of Light Adaptation.

PDE6B PDE6C

2.48e-0826226085644
Pubmed

Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6.

PDE6B PDE6C

1.49e-0746223033484
Pubmed

Rod phosphodiesterase-6 (PDE6) catalytic subunits restore cone function in a mouse model lacking cone PDE6 catalytic subunit.

PDE6B PDE6C

1.49e-0746221799013
Pubmed

Rod nuclear architecture determines contrast transmission of the retina and behavioral sensitivity in mice.

PDE6B PDE6C

1.49e-0746231825309
Pubmed

Structural basis of phosphodiesterase 6 inhibition by the C-terminal region of the gamma-subunit.

PDE6B PDE6C

3.72e-0766219798052
Pubmed

A mouse model for studying cone photoreceptor pathologies.

PDE6B PDE6C

3.72e-0766225034607
Pubmed

Identification of a common non-apoptotic cell death mechanism in hereditary retinal degeneration.

PDE6B PDE6C

5.21e-0776225392995
Pubmed

Retinal degeneration mutants in the mouse.

PDE6B PDE6C

1.93e-06136211853768
Pubmed

DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration.

PDE6B PDE6C

2.25e-06146221297615
Pubmed

In vivo function of the orphan nuclear receptor NR2E3 in establishing photoreceptor identity during mammalian retinal development.

PDE6B PDE6C

2.25e-06146216868010
Pubmed

Dorsal root ganglion axon bifurcation tolerates increased cyclic GMP levels: the role of phosphodiesterase 2A and scavenger receptor Npr3.

PDE6B PDE6C

5.20e-06216227740716
Pubmed

Overview of PDEs and their regulation.

PDE6B PDE6C

7.43e-06256217307970
Pubmed

Requirement of the Mowat-Wilson Syndrome Gene Zeb2 in the Differentiation and Maintenance of Non-photoreceptor Cell Types During Retinal Development.

PDE6B PDE6C

1.83e-05396229922981
Pubmed

Mouse model resources for vision research.

PDE6B PDE6C

2.03e-05416221052544
Pubmed

Mouse models of ocular diseases.

PDE6B PDE6C

2.34e-05446216332269
Pubmed

A hybrid photoreceptor expressing both rod and cone genes in a mouse model of enhanced S-cone syndrome.

PDE6B PDE6C

7.99e-05816216110338
Pubmed

Decreased Anxiety-Related Behaviour but Apparently Unperturbed NUMB Function in Ligand of NUMB Protein-X (LNX) 1/2 Double Knockout Mice.

FERMT2 EML3

1.47e-041106227889896
GeneFamilyPhosphodiesterases

PDE6B PDE6C

1.68e-052452681
CoexpressionDESCARTES_MAIN_FETAL_PHOTORECEPTOR_CELLS

PDE6B PDE6C

2.18e-0410162M40100
CoexpressionNRL_DN.V1_UP

PDE6B EML3

4.01e-0413762M2798
CoexpressionGSE40274_CTRL_VS_IRF4_TRANSDUCED_ACTIVATED_CD4_TCELL_UP

HACD4 TBC1D9

5.60e-0416262M9085
CoexpressionGSE21360_SECONDARY_VS_TERTIARY_MEMORY_CD8_TCELL_DN

HACD4 EML3

5.95e-0416762M7621
CoexpressionLI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_UP

PDE6B TBC1D9

7.14e-0418362M12621
CoexpressionGSE30971_CTRL_VS_LPS_STIM_MACROPHAGE_WBP7_KO_4H_UP

FERMT2 TBC1D9

8.18e-0419662M8714
CoexpressionGSE14308_TH1_VS_NATURAL_TREG_DN

HACD4 EML3

8.43e-0419962M3381
CoexpressionGSE33513_TCF7_KO_VS_HET_EARLY_THYMIC_PROGENITOR_UP

FERMT2 PDE6B

8.43e-0419962M5105
CoexpressionGSE36009_WT_VS_NLRP10_KO_DC_LPS_STIM_UP

HACD4 EML3

8.43e-0419962M8769
CoexpressionGSE14908_RESTING_VS_HDM_STIM_CD4_TCELL_NONATOPIC_PATIENT_UP

FERMT2 EML3

8.52e-0420062M7086
CoexpressionGSE41176_WT_VS_TAK1_KO_ANTI_IGM_STIM_BCELL_3H_DN

FERMT2 TBC1D9

8.52e-0420062M9950
CoexpressionHE_LIM_SUN_FETAL_LUNG_C0_MID_MESOTHELIAL_CELL

HACD4 TBC1D9 EML3

8.88e-0495563M45680
ToppCellLPS_only-Hematopoietic_Mast-Mast_cells-Mast-cells|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

HACD4 PDE6B

1.35e-041366282d7f90ef2a63a3137c331efd68c036cd0db3ac1
ToppCellfacs-Skin-nan-18m-Myeloid-nan|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

HACD4 TBC1D9

1.62e-041496223a1b95c12f2e3708dc003e13fab423e89821f11
ToppCellfacs-Skin-nan-18m-Myeloid|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

HACD4 TBC1D9

1.62e-0414962bb18a18b891af85849b9658d774053f839c9a8e1
ToppCellfacs-Skin-nan-18m-Myeloid-macrophage|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

HACD4 TBC1D9

1.62e-0414962c53a3226adc8fd0eaaa842b6a96442287580cbe0
ToppCellTCGA-Uterus-Primary_Tumor-Uterine_Carcinoma-Uterine_Carcinosarcoma-3|TCGA-Uterus / Sample_Type by Project: Shred V9

HACD4 TBC1D9

1.94e-0416362d64dd39b077105c73e570ccef70f0e74a2c586ac
ToppCellfacs-Marrow-T_cells-18m-Myeloid-basophil|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

HACD4 FERMT2

2.01e-04166620975fc165bcc7e85f053d9d0244fffe407c23571
ToppCellfacs-Marrow-T_cells-18m-Myeloid-basophil|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

HACD4 FERMT2

2.01e-0416662c22b0f3bf990d94b615a3aacee5de548da2db628
ToppCellrenal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_2|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

FERMT2 TBC1D9

2.34e-0417962666072c0e8448dbaec1683d18368ec2502453f90
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_2|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

FERMT2 TBC1D9

2.42e-04182625f513bbb7125956eb528e3120de3fd776770a7c3
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_2|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

FERMT2 TBC1D9

2.44e-04183622e831a4d99c6f983793df71c0994124c943c6da9
ToppCellP28-Mesenchymal-developing_mesenchymal_cell-mesenchymal_myogenic_precursor_(Axin2+)|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

HACD4 FERMT2

2.47e-041846223c24ab5786af33d605bc445d06117b9da6c6331
ToppCellP15-Mesenchymal-developing_mesenchymal_cell-mesenchymal_myogenic_precursor_(Axin2+)|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

HACD4 FERMT2

2.50e-0418562b1e84228c95be8ccf7c3c1afb66b71ffb93cf61e
ToppCellrenal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

FERMT2 TBC1D9

2.60e-04189627eb8f5a951e80f1cfac4d7c9eb169f4eb100c917
ToppCellrenal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_1|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

FERMT2 TBC1D9

2.60e-0418962975c0f079903ae36b0ffa54e86294d42ec7697de
ToppCellPND10-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-Pericyte-Pericyte_mature|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

HACD4 FERMT2

2.63e-04190627fec459cd2ad12c2923a03d098289337c0a4c1d3
ToppCellP07-Mesenchymal-developing_mesenchymal_cell-mesenchymal_myogenic_precursor_(Axin2+)|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

HACD4 FERMT2

2.66e-04191622ad717b59215ad8d933e9637d363b65d7298e5d4
ToppCellPND14-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-Pericyte|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

HACD4 FERMT2

2.69e-0419262158cc5736f154da1cb3186ffbf186eae10483e48
ToppCellPND14-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-Pericyte-Pericyte_mature|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

HACD4 FERMT2

2.69e-0419262f4ff62ac9c53eafbe917706de9af8b2d4bded4d4
ToppCellkidney_cells-Hypertensive_with+without-CKD-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Degenerative_Distal_Convoluted_Tubule_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

FERMT2 TBC1D9

2.69e-041926246ea8f4f292db70420b378c6fa3e55e99413679c
ToppCellkidney_cells-Hypertensive_with+without-CKD-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

FERMT2 TBC1D9

2.77e-041956260d08fb27469d1e247bc47b651d7023ba82cf92f
ToppCellkidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

FERMT2 TBC1D9

2.80e-0419662f40d10ea7714067585493fdc89744714aa427de8
ToppCellkidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Degenerative_Distal_Convoluted_Tubule_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

FERMT2 TBC1D9

2.80e-0419662b8350340d86e4524e9616a427e7f2e116a6fb3be
ToppCellLPS_IL1RA-Mesenchymal_myocytic-Pericyte-Pericyte_2|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

HACD4 FERMT2

2.91e-0420062cf883ba5dbe6350b93142d625a52b25ff2a8bb63
ToppCellLPS_IL1RA-Hematopoietic_Myeloid-Granulocytic_cells-Mast-cells|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

HACD4 PDE6B

2.91e-04200622200a621da1634728a49b1706e422e3e78b1f3bf
ToppCellLPS_IL1RA_TNF-Mesenchymal_myocytic-Pericyte-Pericyte_2|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type

HACD4 FERMT2

2.91e-0420062d2fcd3bd7c3223875f027eeb48ff621192a5f242
DrugGlimepiride [93479-97-1]; Down 200; 8.2uM; MCF7; HT_HG-U133A

PDE6B TBC1D9 EML3

1.18e-05193634973_DN
DrugEsculin Hydrate [531-75-9]; Down 200; 11.8uM; HL60; HT_HG-U133A

PDE6B PDE6C EML3

1.31e-05200633052_DN
Drug2gg8

PDE6B PDE6C

3.84e-053762CID006914647
Drugperformic acid

PDE6B PDE6C

7.63e-055262CID000066051
Drugsildenafil

PDE6B PDE6C

2.61e-049662CID000005212
DrugPDEs

PDE6B PDE6C

3.81e-0411662CID003036959
Drugzaprinast

PDE6B PDE6C

5.62e-0414162CID000005722
DrugNSC625381

FERMT2 PDE6B

5.94e-0414562CID000002592
Drugmilrinone

PDE6B PDE6C

6.36e-0415062CID000004197
DrugAC1L19O6

PDE6B PDE6C

6.87e-0415662CID000025750
DrugP-NE

PDE6B PDE6C

8.06e-0416962CID000446755
Drugglycerol-3-phosphocholine

PDE6B PDE6C

8.34e-0417262CID000000823
Drugpapaverine

PDE6B PDE6C

8.73e-0417662CID000004680
DrugSecurinine [5610-40-2]; Down 200; 18.4uM; HL60; HT_HG-U133A

TBC1D9 EML3

9.85e-04187622729_DN
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A

TBC1D9 EML3

1.02e-03190626943_DN
Drugretinoic acid; Down 200; 1uM; MCF7; HT_HG-U133A_EA

FERMT2 EML3

1.03e-0319162991_DN
DrugChelidonine monohydrate (+) [476-32-4]; Up 200; 10.8uM; MCF7; HT_HG-U133A

FERMT2 EML3

1.03e-03191626236_UP
Drugvinblastine sulfate; Up 200; 0.1uM; PC3; HT_HG-U133A

FERMT2 EML3

1.04e-03192627556_UP
Drugretinoic acid; Down 200; 1uM; MCF7; HT_HG-U133A_EA

PDE6B PDE6C

1.04e-0319262849_DN
Drug17-AAG; Down 200; 1uM; HL60; HT_HG-U133A

TBC1D9 PDE6C

1.04e-03192622666_DN
DrugClotrimazole [23593-75-1]; Up 200; 11.6uM; MCF7; HT_HG-U133A

PDE6B EML3

1.05e-03193626207_UP
DrugPiperine [94-62-2]; Down 200; 14uM; MCF7; HT_HG-U133A

FERMT2 EML3

1.05e-03193623263_DN
DrugGabapentin [60142-96-3]; Up 200; 23.4uM; MCF7; HT_HG-U133A

PDE6B PDE6C

1.05e-03193627229_UP
DrugPhenylpropanolamine hydrochloride [154-41-6]; Down 200; 21.4uM; PC3; HT_HG-U133A

TBC1D9 EML3

1.05e-03193626699_DN
DrugCefalonium [5575-21-3]; Down 200; 8.8uM; PC3; HT_HG-U133A

PDE6C EML3

1.05e-03193624245_DN
Drug(+,-)-Octopamine hydrochloride [770-05-8]; Down 200; 21uM; PC3; HT_HG-U133A

PDE6C EML3

1.05e-03193625050_DN
DrugClofazimine [2030-63-9]; Down 200; 8.4uM; PC3; HT_HG-U133A

PDE6B PDE6C

1.06e-03194624682_DN
DrugICI 182,780; Down 200; 1uM; PC3; HT_HG-U133A

FERMT2 EML3

1.06e-03194624429_DN
DrugIndapamide [26807-65-8]; Down 200; 10.6uM; PC3; HT_HG-U133A

TBC1D9 EML3

1.06e-03194624335_DN
DrugMitoxantrone dihydrochloride [70476-82-3]; Up 200; 7.8uM; MCF7; HT_HG-U133A

PDE6B PDE6C

1.06e-03194625354_UP
DrugSpiramycin [8025-81-8]; Down 200; 4.8uM; MCF7; HT_HG-U133A

FERMT2 EML3

1.06e-03194623419_DN
DrugIndoprofen [31842-01-0]; Down 200; 14.2uM; PC3; HT_HG-U133A

TBC1D9 PDE6C

1.06e-03194624249_DN
Drug0316684-0000 [391209-55-5]; Down 200; 10uM; PC3; HT_HG-U133A

FERMT2 TBC1D9

1.06e-03194627098_DN
DrugAmikacin hydrate [37517-28-5]; Down 200; 6.6uM; PC3; HT_HG-U133A

TBC1D9 EML3

1.06e-03194626715_DN
DrugFelodipine [72509-76-3]; Down 200; 10.4uM; PC3; HT_HG-U133A

PDE6B EML3

1.06e-03194626695_DN
DrugIndomethacin [53-86-1]; Down 200; 11.2uM; PC3; HT_HG-U133A

PDE6C EML3

1.06e-03194625049_DN
Drugestradiol; Down 200; 0.01uM; PC3; HT_HG-U133A

PDE6B PDE6C

1.07e-03195625910_DN
DrugAlfaxalone [23930-19-0]; Down 200; 12uM; MCF7; HT_HG-U133A

PDE6B TBC1D9

1.07e-03195626514_DN
DrugDoxylamine succinate [562-10-7]; Down 200; 10.2uM; PC3; HT_HG-U133A

PDE6C EML3

1.07e-03195624235_DN
DrugAlfuzosin hydrochloride [81403-68-1]; Down 200; 9.4uM; PC3; HT_HG-U133A

TBC1D9 EML3

1.07e-03195624644_DN
DrugClioquinol [130-26-7]; Down 200; 13uM; HL60; HT_HG-U133A

PDE6C EML3

1.07e-03195623084_DN
DrugChelidonine monohydrate (+) [476-32-4]; Up 200; 10.8uM; PC3; HT_HG-U133A

FERMT2 PDE6C

1.07e-03195625760_UP
Drug(-)-depudecin; Up 200; 1uM; MCF7; HT_HG-U133A_EA

PDE6B PDE6C

1.07e-0319562874_UP
DrugMycophenolic acid [24280-93-1]; Down 200; 12.4uM; PC3; HT_HG-U133A

PDE6B EML3

1.07e-03195624019_DN
DrugAmphotericin B [1397-89-3]; Up 200; 4.4uM; PC3; HT_HG-U133A

PDE6B EML3

1.07e-03195626303_UP
Drugradicicol, diheterospora chlamydosporia; Down 200; 0.1uM; MCF7; HT_HG-U133A

TBC1D9 EML3

1.07e-03195626979_DN
DrugMebhydroline 1,5-naphtalenedisulfonate [6153-33-9]; Up 200; 4.8uM; PC3; HT_HG-U133A

PDE6B EML3

1.07e-03195624211_UP
DrugCiprofloxacin hydrochloride [93107-08-5]; Up 200; 10.8uM; MCF7; HT_HG-U133A

FERMT2 EML3

1.07e-03195625299_UP
DrugProbucol [23288-49-5]; Down 200; 7.8uM; MCF7; HT_HG-U133A

FERMT2 PDE6B

1.07e-03195625626_DN
DrugCyclopentolate hydrochloride [5870-29-1]; Down 200; 12.2uM; PC3; HT_HG-U133A

FERMT2 EML3

1.08e-03196625734_DN
DrugLumicolchicine gamma [6901-14-0]; Up 200; 10uM; HL60; HT_HG-U133A

TBC1D9 EML3

1.08e-03196621317_UP
DrugBeclomethasone dipropionate [5534-09-8]; Down 200; 7.6uM; PC3; HT_HG-U133A

PDE6B PDE6C

1.08e-03196624580_DN
DrugIsoetharine mesylate salt [7279-75-6]; Down 200; 12uM; PC3; HT_HG-U133A

FERMT2 PDE6C

1.08e-03196625812_DN
DrugS-(+)-ibuprofen [51146-56-6]; Down 200; 19.4uM; HL60; HT_HG-U133A

PDE6C EML3

1.08e-03196623094_DN
DrugMoxonidine [75438-57-2]; Down 200; 16.6uM; HL60; HT_HG-U133A

TBC1D9 EML3

1.08e-03196622923_DN
DrugCefamandole sodium salt [30034-03-8]; Down 200; 8.2uM; MCF7; HT_HG-U133A

TBC1D9 PDE6C

1.08e-03196624718_DN
DrugCimetidine [51481-61-9]; Down 200; 15.8uM; PC3; HT_HG-U133A

FERMT2 EML3

1.08e-03196624063_DN
DrugCorynanthine hydrochloride [66634-44-4]; Down 200; 10.2uM; PC3; HT_HG-U133A

TBC1D9 PDE6C

1.08e-03196624227_DN
Drugfluphenazine dihydrochloride; Down 200; 10uM; MCF7; HT_HG-U133A

FERMT2 EML3

1.08e-03196621662_DN
DrugPseudopelletierine hydrochloride [6164-62-1]; Up 200; 21uM; PC3; HT_HG-U133A

PDE6B EML3

1.08e-03196625828_UP
DrugRitodrine hydrochloride [23239-51-2]; Down 200; 12.4uM; PC3; HT_HG-U133A

TBC1D9 PDE6C

1.08e-03196624619_DN
DrugSulfamethazine sodium salt [1981-58-4]; Up 200; 13.4uM; HL60; HT_HG-U133A

PDE6B TBC1D9

1.08e-03196622560_UP
DrugLY294002; Up 200; 0.1uM; MCF7; HG-U133A

FERMT2 EML3

1.08e-0319662424_UP
DrugAminopurine, 6-benzyl [1214-39-7]; Up 200; 17.8uM; PC3; HT_HG-U133A

TBC1D9 PDE6C

1.08e-03196623726_UP
DrugTenoxicam [59804-37-4]; Down 200; 11.8uM; MCF7; HT_HG-U133A

FERMT2 PDE6C

1.08e-03196624182_DN
DrugEconazole nitrate [24169-02-6]; Down 200; 9uM; HL60; HT_HG-U133A

TBC1D9 EML3

1.08e-03196622396_DN
DrugCyclosporin A [59865-13-3]; Down 200; 3.4uM; PC3; HT_HG-U133A

PDE6B PDE6C

1.08e-03196624586_DN
DrugDienestrol [84-17-3]; Down 200; 15uM; MCF7; HT_HG-U133A

FERMT2 EML3

1.08e-03196623448_DN
DrugRolitetracycline [751-97-3]; Up 200; 7.6uM; MCF7; HT_HG-U133A

FERMT2 EML3

1.08e-03196625331_UP
DrugOrlistat; Up 200; 10uM; PC3; HT_HG-U133A

FERMT2 TBC1D9

1.08e-03196626420_UP
DrugTimolol maleate salt [26921-17-5]; Up 200; 9.2uM; PC3; HT_HG-U133A

TBC1D9 EML3

1.08e-03196624685_UP
DrugAcebutolol hydrochloride [34381-68-5]; Down 200; 10.8uM; PC3; HT_HG-U133A

PDE6B EML3

1.08e-03196626631_DN
DrugSkimmianine [83-95-4]; Down 200; 15.4uM; PC3; HT_HG-U133A

TBC1D9 EML3

1.09e-03197625766_DN
Drugaspirin, USP; Up 200; 100uM; MCF7; HT_HG-U133A_EA

PDE6B PDE6C

1.09e-0319762984_UP
DrugCyclizine hydrochloride [303-25-3]; Down 200; 13.2uM; PC3; HT_HG-U133A

PDE6C EML3

1.09e-03197625100_DN
DrugCarteolol hydrochloride [51781-21-6]; Down 200; 12.2uM; PC3; HT_HG-U133A

TBC1D9 EML3

1.09e-03197624096_DN
DrugHexestrol [84-16-2]; Up 200; 14.8uM; MCF7; HT_HG-U133A

PDE6B EML3

1.09e-03197626252_UP
DrugLiothyronine [6893-02-3]; Down 200; 6.2uM; HL60; HT_HG-U133A

PDE6B PDE6C

1.09e-03197622984_DN
DrugCefotaxime sodium salt [64485-93-4]; Down 200; 8.4uM; MCF7; HT_HG-U133A

TBC1D9 EML3

1.09e-03197627186_DN
DrugNorgestrel-(-)-D [797-63-7]; Down 200; 12.8uM; MCF7; HT_HG-U133A

FERMT2 EML3

1.09e-03197623406_DN
DrugSerotonin hydrochloride [153-98-0]; Down 200; 18.8uM; PC3; HT_HG-U133A

PDE6B PDE6C

1.09e-03197624673_DN
DrugEpirizole [18694-40-1]; Down 200; 17uM; PC3; HT_HG-U133A

FERMT2 TBC1D9

1.09e-03197621803_DN
DrugS(-)Eticlopride hydrochloride [97612-24-3]; Down 200; 10.6uM; HL60; HT_HG-U133A

TBC1D9 EML3

1.09e-03197623056_DN
DrugPF-00539745-00 [351321-33-0]; Up 200; 10uM; PC3; HT_HG-U133A

PDE6C EML3

1.09e-03197625939_UP
DrugAtractyloside potassium salt [102130-43-8]; Down 200; 5uM; MCF7; HT_HG-U133A

PDE6B PDE6C

1.09e-03197624717_DN
DrugAustricine [10180-88-8]; Up 200; 14.2uM; MCF7; HT_HG-U133A

PDE6B EML3

1.09e-03197624797_UP
Drug(-)-Adenosine 3',5'-cyclic monophosphate [60-92-4]; Down 200; 12.2uM; PC3; HT_HG-U133A

TBC1D9 PDE6C

1.09e-03197625108_DN
DrugDexamethasone acetate [1177-87-3]; Up 200; 9.2uM; MCF7; HT_HG-U133A

PDE6B EML3

1.09e-03197626271_UP
DrugTerconazole [67915-31-5]; Down 200; 7.6uM; PC3; HT_HG-U133A

PDE6B PDE6C

1.09e-03197624583_DN
DrugClonidine hydrochloride [4205-91-8]; Up 200; 15uM; PC3; HT_HG-U133A

PDE6B PDE6C

1.09e-03197624478_UP
Drugcelecoxib; Down 200; 10uM; MCF7; HT_HG-U133A_EA

PDE6B EML3

1.09e-0319762922_DN
DrugFosfosal [6064-83-1]; Down 200; 18.4uM; MCF7; HT_HG-U133A

PDE6C EML3

1.09e-03197624823_DN
DrugAmiprilose hydrochloride [60414-06-4]; Up 200; 11.8uM; MCF7; HT_HG-U133A

PDE6B PDE6C

1.09e-03197623339_UP
DrugLY 294002; Down 200; 10uM; MCF7; HT_HG-U133A

PDE6B EML3

1.09e-03197625236_DN
DrugMinoxidil [38304-91-5]; Down 200; 19.2uM; MCF7; HT_HG-U133A

FERMT2 EML3

1.09e-03197621496_DN
DrugNiacin [59-67-6]; Down 200; 32.4uM; HL60; HT_HG-U133A

PDE6B TBC1D9

1.09e-03197623043_DN
DrugHecogenin [467-55-0]; Down 200; 9.2uM; HL60; HT_HG-U133A

PDE6B PDE6C

1.09e-03197622716_DN
DrugBenzthiazide [91-33-8]; Down 200; 9.2uM; PC3; HT_HG-U133A

PDE6B PDE6C

1.09e-03197626607_DN
Drug(-)-Adenosine 3',5'-cyclic monophosphate [60-92-4]; Up 200; 12.2uM; MCF7; HT_HG-U133A

PDE6C EML3

1.09e-03197623531_UP
Diseaseretinal degeneration (implicated_via_orthology)

PDE6B PDE6C

1.81e-053362DOID:8466 (implicated_via_orthology)
DiseaseDisorder of eye

PDE6B PDE6C

7.56e-0421262C0015397
Diseaseprostate carcinoma

FERMT2 TBC1D9

1.26e-0289162EFO_0001663

Protein segments in the cluster

PeptideGeneStartEntry
EEVQEKYVVCVLFVF

HACD4

106

Q5VWC8
QVGFIDFVCTFVYKE

PDE6B

771

P35913
QVGFIDFVCTFVYKE

PDE6C

776

P51160
GEVVYFIACVVVLYR

EML3

271

Q32P44
VDCKVVHEFIGGYIF

FERMT2

641

Q96AC1
AVVVVDCFFYEGIKV

TBC1D9

691

Q6ZT07